--- title: "Why Illumina (ILMN) Stock Climbed And What Investors Are Watching Now" type: "News" locale: "en" url: "https://longbridge.com/en/news/296706451.md" description: "Illumina (ILMN) secured a $1B revolving credit facility and completed a $300m fixed income offering, enhancing balance sheet flexibility. The stock has surged over 115% in the past year, trading above analyst targets but showing mixed valuation signals: narrative models suggest it is overvalued at $219.40 versus a fair value of $172.53, while DCF models indicate undervaluation at $259.47. Key risks include patent disputes in Germany and regulatory uncertainty in China." datetime: "2026-08-23T15:45:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296706451.md) - [en](https://longbridge.com/en/news/296706451.md) - [zh-HK](https://longbridge.com/zh-HK/news/296706451.md) generator: "portal-rs" --- # Why Illumina (ILMN) Stock Climbed And What Investors Are Watching Now ## Why Illumina’s New Financing Matters For Stock Investors Illumina (ILMN) has just put in place a new US$1b senior unsecured revolving credit facility and completed a roughly US$300m fixed income offering. These financing steps give investors fresh information on the company’s balance sheet flexibility. The new credit agreement runs for five years, with options to extend to 2031. It replaces Illumina’s prior facility that was terminated on 13 August 2026. As of that date, the company reported no borrowings outstanding under the new revolver. See our latest analysis for Illumina. These financing moves come after a strong run in Illumina’s stock, with a 51.93% 3 month share price return and a 115.52% 1 year total shareholder return. This suggests momentum and renewed appetite for the company’s risk profile. If Illumina’s recent surge has you rethinking your exposure to genomics and AI in healthcare, it can be useful to compare with other specialists through our 40 healthcare AI stocks After a 116% 1 year return, Illumina now trades above the average analyst target yet still screens at a discount to some fair value estimates. Is the market applying sensible caution or leaving potential upside unrecognized? ## Most Popular Narrative: 27.2% Overvalued Illumina closed at $219.40 while the most followed narrative pegs fair value closer to $172.53, using a 7.99% discount rate and detailed long term forecasts. > *Strong and resilient growth in clinical applications especially oncology, genetic disease testing, and reproductive health continues to expand as genomic technologies become the standard of care, supporting both recurring revenues from consumables and long term earnings visibility.* *Read the complete narrative.* Read the complete narrative. Want to see what is driving that gap between price and fair value? The narrative leans heavily on steady revenue expansion, firmer margins, and a richer future earnings multiple. Curious which assumptions really move the model? **Result: Fair Value of $172.53 (OVERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, Illumina’s story still carries real pressure points, including ongoing patent disputes in Germany and regulatory uncertainty in China that could disrupt instrument and consumables demand. Find out about the key risks to this Illumina narrative. ## Another View On Illumina’s Valuation The narrative-based fair value of $172.53 points to Illumina as 27.2% overvalued. Yet the SWS DCF model tells a different story, with a future cash flow value of $259.47 per share that suggests the stock is trading at a discount. Which set of assumptions appears more realistic to you? To understand what sits behind that future cash flow value, and how sensitive it is to revenue, margins, and discount rates, take a closer look at the SWS DCF model for Illumina through the Look into how the SWS DCF model arrives at its fair value. ILMN Discounted Cash Flow as at Aug 2026 Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Illumina for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. ## Next Steps With Illumina’s mixed signals on valuation, risks, and financing in mind, do not wait for consensus to form before you review the details yourself and decide where you stand. Start by weighing both sides of the story through the 2 key rewards and 3 important warning signs. ## Looking For More Investment Ideas Beyond Illumina? If Illumina has sharpened your focus on stock selection, broaden your watchlist now so you do not miss other potential opportunities taking shape across the market. - Target dependable value by scanning for companies that combine quality fundamentals with attractive pricing through the 48 high quality undervalued stocks. - Strengthen your income stream by reviewing stocks that offer resilient payouts using the 12 dividend fortresses. - Prioritize resilience by searching for companies with lower risk profiles and steadier fundamentals through the 75 resilient stocks with low risk scores. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [ILMN.US](https://longbridge.com/en/quote/ILMN.US.md) ## Related News & Research - [Top Illumina Executive Unloads Shares in Notable Insider Move](https://longbridge.com/en/news/296572634.md) - [Illumina SVP Jakob Wedel Christensen sells 1,033 shares worth $197,040.16](https://longbridge.com/en/news/296531379.md) - [Illumina completes $300 million notes offering due 2029](https://longbridge.com/en/news/296140807.md) - [Allworth Financial LP Purchases New Position in Illumina, Inc. $ILMN](https://longbridge.com/en/news/296694311.md) - [OVERSEA CHINESE BANKING Corp Ltd Takes $6.71 Million Position in Illumina, Inc. $ILMN](https://longbridge.com/en/news/296598679.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**